SCHEMBL5568252

SCHEMBL5568252

COc1cc2ncnc(-c3cccc(C(N)=O)c3)c2cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.56
PIK3CA P42336 3/20 0.56
PIK3CB P42338 3/20 0.56
PIK3CG P48736 3/20 0.56
KCNH2 Q12809 1/20 0.56
KIT P10721 4/20 0.55
EGFR P00533 2/20 0.49
PGK1 P00558 1/20 0.49
ERBB2 P04626 1/20 0.49
AURKA O14965 2/20 0.48
AURKB Q96GD4 2/20 0.48
KDR P35968 2/20 0.48
MET P08581 1/20 0.48
TEK Q02763 1/20 0.48
PDE10A Q9Y233 3/20 0.48
RAF1 P04049 1/20 0.48
BRAF P15056 1/20 0.48
MAPK14 Q16539 1/20 0.47
ENPP1 P22413 1/20 0.47
FYN P06241 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182533 0.89 PIK3CD (0.71) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL5569427 0.86 KIT (0.58) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL5568255 0.81 KIT (0.64) KITEGFRERBB2KDRRAF1
SCHEMBL6181412 0.79 EGFR (0.63) PIK3CDPIK3CAPIK3CBPIK3CGKIT
SCHEMBL4782102 0.79 WHR1 (0.61) KITEGFRKDR
SCHEMBL2126095 0.78 EGFR (0.61) KITEGFRKDRRAF1MAPK14
SCHEMBL2125179 0.78 EGFR (0.61) KITEGFRERBB2KDRMET
SCHEMBL29055018 0.78 ENPP1 (0.60) PIK3CDPIK3CAPIK3CBPIK3CGKIT
SCHEMBL30080208 0.78 ENPP1 (0.60) PIK3CDPIK3CAPIK3CBPIK3CGKIT
SCHEMBL5569012 0.78 EGFR (0.72) EGFRERBB2AURKAAURKBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT PIK3CD 978/4885PIK3CA 1206/4885PIK3CB 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.